A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.
about
A Review of the Key Clinical Trials of 2015: Results and ImplicationsProposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative.Transcatheter aortic valve implantation: a revolution in the therapy of elderly and high-risk patients with severe aortic stenosis.Reducing periprocedural complications in transcatheter aortic valve replacement: review of paravalvular leaks, stroke and vascular complications.What can be done for cerebral embolic protection in TAVI? Analysis in the light of 10 years' experience with protected carotid artery stenting.The future of transcatheter aortic valve implantation.Interventional treatment of the aortic valve : Current evidence.Transcatheter aortic valve implantation: current trends and future directions.Cerebral white matter lesion burden is associated with the degree of aortic valve calcification and predicts peri-procedural cerebrovascular events in patients undergoing transcatheter aortic valve implantation (TAVI).Protection from Cerebral Embolic Events During Transcatheter Aortic Valve Replacement.Transcatheter Aortic Valve Replacement: 2015 in Review.Late breaking trials of 2015 in structural heart disease and peripheral artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC, and AHA.Rationale of cerebral protection devices in left atrial appendage occlusion.Renal dysfunction and transcatheter aortic valve implantation outcomes.Incidence and causes of silent and symptomatic stroke following surgical and transcatheter aortic valve replacement: a comprehensive review.Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.Transcatheter aortic valve replacement: perioperative stroke and beyond.Adjuncts to transcatheter aortic valve implantation.Cerebral protection devices for transcatheter aortic valve replacement.Embolic protection in patients undergoing transaortic transcatheter aortic valve replacement: initial experience with the TriGuard HDH embolic deflection device.Perioperative Stroke, In-Hospital Mortality, and Postoperative Morbidity Following Transcatheter Aortic Valve Implantation: A Nationwide Study.The year in cardiology 2015: valvular heart disease.Safety and efficacy of transcatheter aortic valve replacement in intermediate risk patients sets the stage for contemporary trials in lower risk groupsOutcome of Stable Patients With Acute Myocardial Infarction and Coronary Artery Bypass Surgery Within 48 Hours: A Single-Center, Retrospective Experience.The current status of antiplatelet therapy in patients undergoing transcatheter aortic valve implantation.Embolic protection devices for transcatheter aortic valve replacement.Emboli and cognitive state in surgical vs. transcatheter aortic valve replacement.Cognitive Outcomes After Transcatheter Aortic Valve Implantation: A Metaanalysis.Thrombo-embolic prevention after transcatheter aortic valve implantation.Transcatheter Aortic Valve Replacement: Outcomes, Indications, Complications, and Innovations.New generation devices for transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome.Complete filter-based cerebral embolic protection with transcatheter aortic valve replacement.Recent advances in understanding and managing aortic stenosis.The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement.Cerebral protection devices in transcatheter aortic valve replacement: a clinical meta-analysis of randomized controlled trials.Exploring the Difference in Post-procedural Stroke Rates Between Patients with Aortic Stenosis Who Undergo Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement.Cerebral Protection During Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta-Analysis.Understanding Neurologic Complications Following TAVRThe Role of Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Replacement
P2860
Q28077170-7264FA3A-14A9-406D-AE22-890A3D540F8DQ30490857-D61D34ED-45C3-4A6A-80E0-67474359F169Q37747572-B680F4EC-4D32-42BC-B260-964F38ABC8BAQ38619212-C7582E05-0314-461F-B46C-70E96E64F199Q38633224-E4B468ED-4298-4A6C-96DD-D4894374019AQ38636454-8F83CA67-2B1E-46A2-BC8F-528DAC74C0F5Q38673442-5BD3759A-AC88-4075-9366-3114F70D5156Q38676944-C0733507-0090-491A-AB2C-A7D4AD8D9238Q38678591-C5E7DAE1-6834-4B70-9B9D-C254900EE903Q38697088-464A2AA4-6635-4461-913B-75CE25D5AC6CQ38728873-30BA7250-2581-4C2E-8B38-E002A9A815E7Q38762518-634B5EBF-AFC0-45F9-8873-0D47CC70C558Q38808853-DAB29DC6-08D7-4261-A6B8-CFE83F74680FQ38820488-BB87BACC-5A8E-4EC6-A2B3-32FA4EC45F46Q38848407-C90361A5-9F97-4814-8C24-65C8E125D4BBQ38981654-9EE3105F-B678-4597-90FF-235EBC00FA0CQ38992381-2832FB6F-81E3-4E26-A23A-BEF7C572ABA1Q39167739-A4A06E36-4F42-49D7-BB7E-44270B4212FAQ39403102-FCCB1150-5385-452B-B12B-7D843F3F363EQ39438016-CFEA84B3-47A0-4FBB-A968-98E59DEE237FQ40060872-BAFD7301-0241-47C8-B231-D2C65D490184Q40847130-ECE04D07-51D9-4547-9356-FC9A04906964Q42384603-7CD14B24-2FC0-49B3-AF82-7D1AF6C80F1DQ47147553-68BCDFBE-B6E7-4DEC-8057-7A1B9A41AB6EQ47160637-9E7132F1-9068-411B-98B1-77E00DF807CDQ47219772-94543CCE-B4D2-4BF4-868E-CFD290980226Q47281656-35D80B19-BBAB-4055-A9C4-40B713A2BA4CQ47437509-A7EC80F7-5FB9-4781-BC37-3608BB35C232Q47903684-D6BC332D-9475-4876-B25F-36F8E8D35778Q47944268-C472D64C-CB33-4BCA-AED8-BC996F1A3181Q47992655-4102FC5B-0AA2-4ACE-BC80-3AC244C498B7Q48087985-814E64AD-1E10-4D0B-B090-F385EC3656E0Q48155124-963CC127-2794-46B4-8EEC-77E8B055A530Q50709545-436FABDF-22C0-4D69-93A5-4D719CCEFB88Q55031800-8D075487-AA05-43FB-8FD8-9FF0E1F2BF1FQ55407938-05FEB479-9E0C-4C1A-95F7-1663A457F895Q55424785-039C0634-9C75-40CE-9887-6804C1D56A42Q57646814-95F0241A-A254-48D1-A807-2E1FAE353D1BQ58571935-E10AE013-DA4E-43DC-BA64-529968B79BBC
P2860
A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@en
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@nl
type
label
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@en
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@nl
prefLabel
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@en
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@nl
P2093
P2860
P356
P1476
A prospective randomized evalu ...... ts from the DEFLECT III trial.
@en
P2093
Adam M Brickman
Alexandra J Lansky
Andreas Baumbach
Cody G Pietras
Daniel Blackman
David Hildick-Smith
Didier Tchetche
Gil Bolotin
Helen Parise
Joachim Schofer
P2860
P304
P356
10.1093/EURHEARTJ/EHV191
P577
2015-05-19T00:00:00Z